Nov 29, 2012 For the past year, top executives at Abbott Laboratories have been trying to convince investors that the impending spinoff of the North Chicago medical-product giantʼs pharmaceutical division, set for January 1, will make the 125-year-old company a more valuable stock holding. At the same time, executives also predict that the new spinoff… Continue reading As Abbott and AbbVie move toward split-up, Wall Street waits
donnamarbury.com 